Pharmacogenomics of the Natriuretic Peptide System in Heart Failure

被引：38
作者：
Abuzaanona A. [1 ]
Lanfear D. [2 ]
机构：
[1] Department of Internal Medicine, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, 48202, MI
[2] Heart and Vascular Institute, Henry Ford Hospital, 2799 W. Grand Boulevard, Detroit, 48202, MI
来源：
Current Heart Failure Reports | 2017年 / 14卷 / 6期
关键词：
Genetics; Genomics; Guanylate cyclase; Heart failure; Natriuretic peptide receptors; Neutral endopeptidase; Personalized medicine; Polymorphism;
D O I：
10.1007/s11897-017-0365-5
中图分类号：
学科分类号：
摘要：
Purpose of Review: Heart failure (HF) continues to be a public health burden despite advances in therapy, and the natriuretic peptide (NP) system is clearly of critical importance in this setting, spawning valuable diagnostic and prognostic testing, such as B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), as well as current and future therapeutics, including recombinant natriuretic peptides (e.g., carperitide, nesiritide) and recently sacubitril, which inhibits the key clearance mechanism for NPs. This article intends to summarize the existing evidence for the role of NP system genetic variation on cardiovascular phenotypes relevant to HF with particular focus on the potential impact on pharmacologic therapies. Recent Findings: Several genes in NP system have been interrogated, in many cases genetic variation impacting protein quantity and function or related disease states. Recent data supports genetic variants potentially impacting pharmacokinetics or dynamics of medications targeting the pathway. Summary: Growing evidence indicates the importance of genetic variation to the functioning of the NP system and its pharmacologic manipulation. © 2017, Springer Science+Business Media, LLC.
引用
收藏
页码：536 / 542
页数：6
相关论文
共 82 条
  • [1] Benjamin E.J., Blaha M.J., Chiuve S.E., Et al., Heart Disease and Stroke Statistics—2017 update: a report from the American Heart Association, Circulation, 135, pp. e146-e603, (2017)
  • [2] Ghani F., Wu A., Bijou R., Et al., Circulating levels of B-type natriuretic peptide (BNP) are useful for diagnosis and are associated with severity of symptoms in chronic heart failure: preliminary data from a multicenter study with Bayer ADVIA Centaur (R) BNP assay, Clin Chem, 49, pp. A67-A68, (2003)
  • [3] Tulevski I.I., Mulder B.J., van Veldhuisen D.J., Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism, J Am Coll Cardiol, 39, (2002)
  • [4] Adlbrecht C., Neuhold S., Hulsmann M., Et al., NT-proBNP as a means of triage for the risk of hospitalisation in primary care, Eur J Cardiovasc Prev Rehabil, (2011)
  • [5] Gale C.P., White J.E., Hunter A., Et al., Predicting mortality and hospital admission in patients with COPD: significance of NT pro-BNP, clinical and echocardiographic assessment, J Cardiovasc Med (Hagerstown), 12, pp. 613-618, (2011)
  • [6] Feola M., Lombardo E., Taglieri C., Piccolo S., Vado A., Plasma BNP and renal failure as prognostic factors of mid-term clinical outcome in congestive heart failure patients, Int J Cardiol, 149, pp. 114-115, (2011)
  • [7] Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial, Jama, 287, pp. 1531-1540, (2002)
  • [8] Colucci W.S., Elkayam U., Horton D.P., Et al., Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group, N Engl J Med, 343, pp. 246-253, (2000)
  • [9] Mangiafico S., Costello-Boerrigter L.C., Andersen I.A., Cataliotti A., Burnett J.C., Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics, Eur Heart J, 34, pp. 886-893c, (2013)
  • [10] McKie P.M., Sangaralingham S.J., Burnett J.C., CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease, Curr Heart Fail Rep, 7, pp. 93-99, (2010)
123456789